Welcome to our dedicated page for Harpoon Therapeutics news (Ticker: HARP), a resource for investors and traders seeking the latest updates and insights on Harpoon Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Harpoon Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Harpoon Therapeutics's position in the market.
Harpoon Therapeutics (NASDAQ: HARP) announced that Gerald McMahon, Ph.D., CEO, will speak at the Cantor Virtual Global Healthcare Conference on September 16, 2020, at 11:20 a.m. ET. The session can be accessed via a live audio webcast on the company's website, which will also host an archived replay afterwards. Harpoon is developing innovative T cell engagers for cancer treatment utilizing its proprietary TriTAC platform. Key projects include HPN424 for prostate cancer and HPN536 for ovarian and pancreatic cancers, currently in clinical trials.
Harpoon Therapeutics, Inc. (NASDAQ: HARP) announced that Dr. Gerald McMahon, President and CEO, will participate in two virtual investor conferences. The first is a fireside chat at Baird’s 2020 Global Healthcare Conference on September 9, 2020, at 3:45 p.m. ET, followed by a panel at Citi's BioPharma Virtual Conference on September 10, 2020, at 10:45 a.m. ET. Investors can access a live audio webcast of the Baird chat on Harpoon's website, with an archived replay available later. Harpoon focuses on T cell engagers for cancer treatment using its proprietary TriTAC platform.
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy firm, announced that its CEO, Gerald McMahon, will speak at two virtual investor conferences. The first is the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 12, 2020, at 11:30 a.m. ET. The second is a panel discussion at the Canaccord Genuity 40th Annual Growth Conference on August 13, 2020, at 1 p.m. ET. Both events will be available via live audio webcast on Harpoon's website. Harpoon specializes in developing T cell engagers for cancer treatment, with several clinical trials currently underway.
Harpoon Therapeutics (NASDAQ: HARP) appointed Joanne Viney, Ph.D., as an independent board member, enhancing its leadership with her extensive immunology expertise. Dr. Viney, who co-founded Pandion Therapeutics, has held key roles at Biogen, Amgen, and Immunex. She replaces Drs. Luke Evnin and Patrick Baeuerle, who step down but will continue to advise Harpoon. This board transition is expected to strengthen Harpoon's focus on advancing its TriTAC® T cell engager platform aimed at treating solid tumors and hematologic malignancies.
Harpoon Therapeutics (NASDAQ: HARP) announced participation in two virtual investor conferences. CEO Gerald McMahon will engage in a fireside chat at the JMP Securities Hematology & Oncology Forum on June 18, 2020, at 4:20 p.m. ET, and at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 2:30 p.m. ET. Live audio webcasts will be accessible in the Investors section of Harpoon's website. Harpoon focuses on developing T cell engagers for cancer treatment, with ongoing trials for multiple product candidates targeting various cancers.
Harpoon Therapeutics (NASDAQ: HARP) announced the presentation of interim Phase 1 data for HPN424, a novel T cell engager for metastatic castration-resistant prostate cancer (mCRPC), at the ASCO 2020 Virtual Scientific Program on May 29, 2020. The study aims to assess safety and efficacy in patients progressing on current treatments. HPN424 is developed using the Tri-functional T cell Activating Construct (TriTAC) platform, targeting prostate-specific membrane antigen (PSMA). Full results will be presented in poster session 5552 / 133.
Summary not available.